To map the evidence available in the literature on the health-related quality of life of women with breast cancer using hormone therapy.
Data sources
This review followed the Joanna Briggs Institute methodological recommendations and Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews reporting guidelines. Searches were performed in nine databases using descriptors, synonyms and keywords; grey literature was also included. The review protocol was registered with the Open Science Framework under doi: http://doi.org/10.17605/OSF.IO/347FM. Inclusion criteria were established according to the Population, Concept, and Context strategy. The selection of studies was performed by two independent reviewers with the aid of RAYYAN software and disagreements were resolved by a third reviewer. The main information from the included articles was grouped into textual categories and presented by means of a narrative synthesis.
Data Summary
A total of 5419 records were identified, of which 42 studies fully met the eligibility criteria. Most were multicenter studies (42.9%) and randomized controlled trials (62%). Most studies addressed anastrozole (39.5%), letrozole (34.2%), and tamoxifen (26.3%), which were studied alone or in combination. The most widely used health-related quality-of-life assessment tool was the EORTC-QLQ-C30. The concomitant use of hormone therapy and cyclin-dependent kinase inhibitors 4 and 6 showed improvement in health-related quality of life.
Conclusion
In recent years there has been an increase in studies focused on health-related quality of life, and the evidence pointed to relevant information on health-related quality of life and the use of endocrine therapy, tamoxifen in combination with aromatase inhibitors, as well as aromatase inhibitor alone and the use of cyclin-dependent kinase 4 and 6.
TrifanescuOGGalesLNSerbanescuGL,et al.Long-term oncological outcome in patients with cervical cancer after 3 trimodality treatment (radiotherapy, platinum-based chemotherapy, and robotic surgery). Medicine (Baltimore)2021; 100: e25271.
2.
Velasco YanezRFrota GoyannaNCarvalho FernandesA, et al.Palliative care in breast cancer during the COVID-19 pandemic: a scoping review. Am J Hospice Palliative Med®2022: 104990912211018. https://doi.org/10.1177/10499091221101879
3.
Anversa SugisakaACMari Salvi AndrzejevskiVRottaI. Validação de Materiais Educativos para Orientação de Pacientes em Tratamento de Câncer de Mama com Hormonioterapia. Revista Brasileira de Cancerologia2020; 66: 1–9.
4.
CorpesEFLeiteKMSilvaDM,et al.Impact of the COVID-19 pandemic on breast cancer screening and early diagnosis. Rev Rene2022; 23: e78620.
5.
CruzDSMColletNNóbregaVM. Qualidade de vida relacionada à saúde de adolescentes com dm1- revisão integrativa. Ciência Saúde Coletiva2018; 23: 973–989.
6.
MoshinaNFalkRSBotteriE,et al.Quality of life among women with symptomatic, screen-detected, and interval breast cancer, and for women without breast cancer: a retrospective cross-sectional study from Norway. Qual Life Res2022; 31: 1057–1068.
7.
RobertsonJFRCheungKLNoguchiS, et al.Health-related quality of life from the FALCON phase III randomised trial of fulvestrant 500 mg versus anastrozole for hormone receptor-positive advanced breast cancer. Eur J Cancer2018; 94: 206–215.
8.
ZhuYCohenSMRosenzweigMQ,et al.Symptom map of endocrine therapy for breast cancer: a scoping review. Cancer Nurs2019; 42: E19–E30.
9.
HoPJGernaatSAMHartmanM,et al.Health-related quality of life in Asian patients with breast cancer: a systematic review. BMJ Open2018; 8: e020512.
HerdmanMBaróE. Calidad de vida asociada a la salud e infección por el VIH. In La medición de la calidad de vida: fundamentos teóricos. (1a, Vol. 1, pp. 19–33). 2000.
14.
BonassaEGatoM. Terapêutica oncológica para Enfermeiros e Farmacêuticos (Atheneu, Ed.; 4o ed). 2012.
15.
OuzzaniMHammadyHFedorowiczZ,et al.Rayyan—a web and mobile app for systematic reviews. Syst Rev2016; 5: 210.
16.
PageMJMoherDBossuytPM, et al.PRISMA 2020 Explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. Br Med J2021: n160. https://doi.org/10.1136/bmj.n160
17.
MassacesiCSabbatiniERocchiMB, et al.Effects of Switching from Tamoxifen to Anastrozole on Tamoxifen-Related Endocrine Symptoms and Quality of Life In Early Breast Cancer Patients. Am J Cancer2006; 5. https://doi.org/1175-6357/06/0006-0433/$39.95/0
18.
CardosoFPaluch-ShimonSSenkusE, et al.5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol2020; 31: 1623–1649.
19.
CamposJADBSpexotoMCBSilvaWRd,et al.European organization for research and treatment of cancer quality of life questionnaire core 30: factorial models to Brazilian cancer patients. Einstein (São Paulo)2018; 16. https://doi.org/10.1590/s1679-45082018ao4132
20.
CriscitielloCSpurdenDPiercyJ, et al.Health-related quality of life among patients with HR+/HER2– early breast cancer. Clin Ther2021; 43: 1228–1244.e4.
21.
CellaDFallowfieldLBarkerP,et al.Quality of life of postmenopausal women in the ATAC (“arimidex”, tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for early breast cancer. Breast Cancer Res Treat2006; 100: 273–284.
22.
OhsumiSShimozumaKOhashiY,et al.Health-related quality of life and psychological distress of breast cancer patients after surgery during a phase III randomized trial comparing continuation of tamoxifen with switching to anastrozole after adjuvant tamoxifen for 1-4 years: n-SAS BC 03. Breast Cancer Res Treat2011; 127: 143–152.
23.
SeberSSolmazDYetisyigitT. Antihormonal treatment associated musculoskeletal pain in women with breast cancer in the adjuvant setting. Onco Targets Ther2016; 9: 4929–4935.
24.
TakeiHOhsumiSShimozumaK,et al.Health-related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: national surgical adjuvant study of breast cancer 04 (N-SAS BC 04). Breast Cancer Res Treat2012; 133: 227–236.
25.
MaunsellELavalUAuH,et al.Health-related quality of life in breast cancer survivors after 5 years of adjuvant tamoxifen. Qual Life Res2005; 14: 1977–2154.
26.
ParkCParkS-KWooA,et al.Health-related quality of life among elderly breast cancer patients treated with adjuvant endocrine therapy: a U.S medicare population-based study. Qual Life Res2022; 31: 1345–1357.
27.
CaoAZhangJLiuX, et al.Health-related quality of life of postmenopausal Chinese women with hormone receptor-positive early breast cancer during treatment with adjuvant aromatase inhibitors: A prospective, multicenter, non-interventional study. Health Qual Life Outcomes2016; 14. https://doi.org/10.1186/s12955-016-0446-2
28.
YagataHOhtsuHKomoikeY, et al.Joint symptoms and health-related quality of life in postmenopausal women with breast cancer who completed 5 years of anastrozole. Support Care Cancer2016; 24: 683–689.
29.
OlufadeTGallicchioLMacDonaldR,et al.Musculoskeletal pain and health-related quality of life among breast cancer patients treated with aromatase inhibitors. Support Care Cancer2015; 23: 447–455.
30.
Pineda-MoncusíMServitjaSTusquetsI, et al.Assessment of early therapy discontinuation and health-related quality of life in breast cancer patients treated with aromatase inhibitors: b-ABLE cohort study. Breast Cancer Res Treat2019; 177: 53–60.
31.
WagnerLIZhaoFGossPE, et al.Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC clinical trials group (CCTG) MA.27 (E1Z03). Breast Cancer Res Treat2018; 169: 537–548.
32.
TairaNIwataHHasegawaY, et al.Health-related quality of life and psychological distress during neoadjuvant endocrine therapy with letrozole to determine endocrine responsiveness in postmenopausal breast cancer. Breast Cancer Res Treat2014; 145: 155–164.
33.
DibbleKEBellizziKMTaxelP, et al.Physical activity and health-related quality of life among postmenopausal women with breast cancer treated with aromatase inhibitors. Support Care Cancer2021; 29: 2385–2394.
34.
JackischCHadjiPHarbeckN, et al.Abstract P5-11-12: Quality of life in the PACT-Programme (Patient’s anastrozole compliance to therapy programme): Influence of a standardized information service on patient satisfaction and health related quality of life in postmenopausal women with early breast cancer (EBC). Poster Session Abstracts2010. P5-11-12-P5-11–12. https://doi.org/10.1158/0008-5472.SABCS10-P5-11-12
35.
WilliamsRBrownJRiderA,et al.239P Impact of clinical characteristics, patients’ perception of treatment goals and endocrine therapy history on HRQOL in HR+, HER2- early stage breast cancer patients. Ann Oncol2020; 31: S336.
36.
DavieACarterGCRiderA, et al.Real-world patient-reported outcomes of women receiving initial endocrine-based therapy for HR+/HER2- advanced breast cancer in five European countries. BMC Cancer2020; 20. https://doi.org/10.1186/s12885-020-07294-2
37.
PinheiroLCWheelerSBReeder-HayesKE,et al.Investigating associations between health-RelatedQuality of life and endocrine therapy underuse inWomen with early-stage breast cancer. J Oncol Prac2017; 13: 326–338.
38.
SheppardVBDashCNomuraS, et al.Physical activity, health-related quality of life, and adjuvant endocrine therapy–related symptoms in women with hormone receptor–positive breast cancer. Cancer2020; 126: 4059–4066.
39.
KikawaYSakamakiKFujisawaT, et al.Health-related quality of life in 2nd-line endocrine therapy for patients with acquired endocrine-resistant postmenopausal er-positive, her2-negative metastatic breast cancer: the horse-bc study. Breast2019; 48: S72–S73.
40.
BurrisHALebrunFRugoHS, et al.Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial. Cancer2013; 119: 1908–1915.
41.
CamponeMBeckJTGnantM, et al.Health-related quality of life and disease symptoms in postmenopausal women with hr+, her2- advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy. Curr Med Res Opin2013; 29: 1463–1473.
42.
TeschHStoetzerODeckerT, et al.Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: results of the single-arm, phase IIIB 4EVER trial. Int J Cancer2019; 144: 877–885.
43.
CetinBWablCAGumusayO. CDK4/6 Inhibitors: mechanisms of resistance and potential biomarkers of responsiveness in breast cancer. Future Oncol2022; 18: 1143–1157.
44.
GoetzMPMartinMTokunagaE, et al.Health-Related quality of life in MONARCH 3: abemaciclib plus an aromatase inhibitor as initial therapy in HR+, HER2− advanced breast cancer. Oncologist2020; 25: e1346–e1354.
45.
HuXCZhangQYSunT, et al.PCN38 Health-Related quality of life (QOL) in monarch PLUS: a phase 3 trial of abemaciclib PLUS nonsteroidal aromatase inhibitor (NSAI) or fulvestrant for women with HR+/HER2- advanced breast cancer (ABC). Value Health2020; 23: S427.
46.
InoueKMasudaNIwataH, et al.Japanese Subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy. Breast Cancer2021; 28: 1038–1050.
47.
KaufmanPAToiMNevenP, et al.Health-Related quality of life in MONARCH 2: abemaciclib plus fulvestrant in hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy. Oncologist2020; 25: e243–e251.
48.
TakahashiMTokunagaEMoriJ, et al.Japanese Subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. Breast Cancer2022; 29: 174–184.
49.
TolaneySBlancasIImY-H,et al.Patients’ quality of life and side effect perceptions in monarchE, a study of abemaciclib plus endocrine therapy in adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer. The Breast2021; 56: S20–S21.
50.
RugoHSDiérasVGelmonKA, et al.Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial. Ann Oncol2018; 29: 888–894.
51.
TibauAMartinezMTRamosM, et al.94MO Quality of life (QoL) with fulvestrant (FUL)/palbociclib (PAL) versus FUL/placebo (PBO) in postmenopausal women with hormone receptor (HR)+/HER2- endocrine sensitive advanced breast cancer (ABC): results from GEICAM/2014-12 (FLIPPER) study. Ann Oncol2021; 32: S63.
52.
LawEGavanjiRWalshS,et al.Palbociclib versus abemaciclib in HR+/HER2- advanced breast cancer: an indirect comparison of patient-reported end points. J Comp Eff Res2022; 11: 109–120.
53.
BeckJNevenPEstevaF, et al.Abstract P6-18-14: patient-reported outcomes with ribociclib-based therapy in hormone receptor-positive, HER2-negative advanced breast cancer: results from the phase III MONALEESA-2, -3, and -7 trials. Poster Session Abstracts2019. P6-18-14. https://doi.org/10.1158/1538-7445.SABCS18-P6-18-14
54.
FaschingPABeckJTChanA, et al.Ribociclib plus fulvestrant for advanced breast cancer: health-related quality-of-life analyses from the MONALEESA-3 study. Breast2020; 54: 148–154.
55.
HarbeckNVillanuevaRFrankeF, et al.Ribociclib (RIB) + tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) in premenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC): MONALEESA-7 patient-reported outcomes (PROs). Ann Oncol2018; 29: viii91.
56.
HarbeckNFrankeFVillanueva-VazquezR, et al.Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7). Ther Adv Med Oncol2020; 12. https://doi.org/10.1177/1758835920943065
57.
HarbeckNHurvitzSBardiaA, et al.Abstract P1-19-06: Patient-reported outcomes, including work productivity, from the MONALEESA-7 trial of ribociclib plus endocrine therapy in patients with HR+/HER2− advanced breast cancer. Poster Session Abstracts2020. P1-19-06-P1-19–06. https://doi.org/10.1158/1538-7445.SABCS19-P1-19-06
58.
JanniWAlbaEBachelotT, et al.First-line ribociclib plus letrozole in postmenopausal women with HR+, HER2− advanced breast cancer: tumor response and pain reduction in the phase 3 MONALEESA-2 trial. Breast Cancer Res Treat2018; 169: 469–479.
59.
VermaSO’ShaughnessyJBurrisHA, et al.Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2. Breast Cancer Res Treat2018; 170: 535–545.
60.
OswaldLBArredondoBKadonoM, et al.A mixed-methods study of cyclin-dependent kinase 4 and 6 inhibitor symptom burden and quality of life among metastatic breast cancer patients and providers. Cancer Med2021; 10: 4823–4831.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
